— § 02
What the literature shows.
Tone lightening (small RCTs)
250–500 mg/d × 12 wk
Modest effect on cheek pigmentation. Heterogeneous trial methodology.
40%
Melasma severity
—
Inconsistent. Topical or oral tranexamic outperform in head-to-head consideration.
20%
Antioxidant biomarker shifts
Small trials
Real shifts in plasma glutathione status. Whether this translates to skin endpoints is the open question.
60%
Marketing 'whitening' claims
—
Not what the literature supports. The category survives on aspiration, not endpoints.
15%